Abstract Objective To investigate the clinical characteristics of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection in children and the risk factors for such infection. Methods A retrospective analysis was conducted among 60 children with CRPA infection (CRPA group) who were hospitalized in Shenzhen Children's Hospital, China Medical University, from January 2018 to September 2023, and 82 children with carbapenem-sensitive Pseudomonas aeruginosa infection during the same period were randomly selected as the control group. A multivariate logistic regression analysis was used to investigate the risk factors for CRPA infection. Results Among the 60 children with CRPA infection, 31 (52%) were admitted to the intensive care unit (ICU), and the lower respiratory tract was the main detection site in 32 children (53%). The univariate analysis showed that sex, history of invasive treatment within 1 year, antibiotic use before admission, presence of underlying condition, ICU admission, invasive procedure after admission, antibiotic use for >14 days, and the type of antibiotics used of ≥3 were associated with CRPA infection (P<0.05). The multivariate logistic regression analysis showed that the history of invasive treatment within 1 year (OR=3.228, P<0.05), antibiotic use before admission (OR=4.052, P<0.05), antibiotic use for >14 days (OR=4.961, P<0.05), and the type of antibiotics used of ≥3 (OR=3.687, P<0.05) were independent risk factors for CRPA infection in children. Conclusions CRPA infection in children may be associated with a history of invasive treatment within the past year, antibiotic use before admission, duration of antibiotic use after admission, and the diversity of antibiotic types used.
PENG Yi-Lu,WANG Hong-Mei,LI Chi et al. Clinical characteristics and risk factors of carbapenem-resistant Pseudomonas aeruginosa infection in children[J]. CJCP, 2024, 26(11): 1169-1175.
PENG Yi-Lu,WANG Hong-Mei,LI Chi et al. Clinical characteristics and risk factors of carbapenem-resistant Pseudomonas aeruginosa infection in children[J]. CJCP, 2024, 26(11): 1169-1175.
Sader HS, Dale GE, Rhomberg PR, et al. Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China[J]. Antimicrob Agents Chemother, 2018, 62(7): e00311-18. PMID: 29686157. PMCID: PMC6021639. DOI: 10.1128/AAC.00311-18.
Zhang D, Cui K, Wang T, et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection or colonization in a Chinese teaching hospital[J]. J Infect Dev Ctries, 2018, 12(8): 642-648. PMID: 31958327. DOI: 10.3855/jidc.10150.
Li L, Huang Y, Tang Q, et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in children[J]. Pediatr Infect Dis J, 2022, 41(8): 642-647. PMID: 35446814. DOI: 10.1097/INF.0000000000003563.
